SCHEMBL22265698

SCHEMBL22265698

CCCCCCCCCCCc1ccc(-c2noc(C3CN(C(=O)OC(C)(C)C)C3)n2)cc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SPHK2 Q9NRA0 5/20 0.49
SPHK1 Q9NYA1 2/20 0.49
FAAH O00519 1/20 0.45
MGLL Q99685 1/20 0.45
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.44
HDAC4 P56524 4/20 0.43
HDAC6 Q9UBN7 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
GRM5 P41594 3/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22265606 1.00 SPHK2 (0.49) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22266076 1.00 SPHK2 (0.49) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL29523421 0.93 HTT (0.52) SPHK2SPHK1CYP1A2POLBCYP3A4
SCHEMBL29523364 0.93 HTT (0.52) SPHK2SPHK1CYP1A2POLBCYP3A4
SCHEMBL22265338 0.88 SPHK2 (0.62) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22265916 0.88 SPHK2 (0.62) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22265397 0.87 SPHK2 (0.43) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22265297 0.87 SPHK2 (0.43) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22265443 0.87 SPHK2 (0.43) SPHK2SPHK1FAAHMGLLCYP1A2
SCHEMBL22265445 0.87 SPHK2 (0.43) SPHK2SPHK1FAAHMGLLCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
EP-3914592-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2021-12-01 EP disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 SPHK2 50/4885SPHK1 435/4885FAAH 4190/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 SPHK2 6/4885SPHK1 16/4885FAAH 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.